From multimarker approach to multiplex assays in acute coronary syndromes: What are we searching for?

References

• Libby P. Current concept of the pathogenesis of the acute coronary syndromes. Circulation 2001;104:365–72.
   PubMed Web of Science ®Google Scholar
• Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1760–3.
   Google Scholar
• Parikh SV, de Lemos JA. Biomarkers in cardiovascular disease: integrating pathophysiology into clinical practice. Am J Med Sci. 2006;332:186–97.
   PubMedGoogle Scholar
• Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res. 2002;53:31–7.
   PubMed Web of Science ®Google Scholar
• Ferraro S, Lupi A, Marano G, Rossi L, Ciardi L, Vendramin C, . Different patterns of NT-proBNP secretion in acute coronary syndromes. Clin Chim Acta 2009;402:176–81.
   Google Scholar
• Boyle MD, Hess JL, Nuara AA, Buller RM. Application of immunoproteomics to rapid cytokine detection. Methods 2006;38:342–50.
   Google Scholar
• Nielsen UB, Geierstanger BH. Multiplexed sandwich assays in microarray format. J Immunol Methods 2004 290:107–20.
   PubMed Web of Science ®Google Scholar
• Apple FS, Pearce LA, Smith SW, Kaczmarek JM, Murakami MM. Role of monitoring changes in sensitive cardiac troponin I assay results for early diagnosis of myocardial infarction and prediction of risk of adverse events. Clin Chem. 2009;55:930–7.
   PubMed Web of Science ®Google Scholar
• Ray KK, Cannon CP, Cairns R, Morrow DA, Rifai N, Kirtane AJ, . PROVE IT-TIMI 22 investigators relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2005;46:1417–24.
   PubMed Web of Science ®Google Scholar
• Eggers KM, Oldgren J, Nordenskjöld A, Lindahl B. Diagnostic value of serial measurement of cardiac markers in patients with chest pain: Limited value of adding myoglobin to troponin I for exclusion of myocardial infarction. Am Heart J. 2004;148:574–81
   PubMed Web of Science ®Google Scholar
• Casals G, Filella X, Augé JM, Bedini JL. Impact of ultrasensitive cardiac troponin I dynamic changes in the new universal definition of myocardial infarction. Am J Clin Pathol. 2008;130:964–8.
   PubMed Web of Science ®Google Scholar
• Howes JM, Keen JN, Findlay JB, Carter AM. The application of proteomics technology to thrombosis research: The identification of potential therapeutic targets in cardiovascular disease. Diab Vasc Dis Res. 2008;5:205–12.
   PubMed Web of Science ®Google Scholar
• McCann CJ, Glover BM, Menown IB, Moore MJ, McEneny J, Owens CG, . Prognostic value of a multimarker approach for patients presenting to hospital with acute chest pain. Am J Cardiol. 2009;103:22–8.
   PubMed Web of Science ®Google Scholar
• Eggers KM, Dellborg M, Oldgren J, Swahn E, Venge P, Lindahl B. Risk prediction in chest pain patients by biochemical markers including estimates of renal function. Int J Cardiol. 2008;128:207–13.
   Web of Science ®Google Scholar
• Hulthe J, McPheat W, Samnegård A, Tornvall P, Hamsten A, Eriksson P. Plasma interleukin (IL)-18 concentrations is elevated in patients with previous myocardial infarction and related to severity of coronary atherosclerosis independently of C-reactive protein and IL-6. Atherosclerosis 2006 188:450–4.
   PubMedGoogle Scholar
• Tataru MC, Heinrich J, Junker R, Schulte H, von Eckard-stein A, Assmann G, . C-reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris. Eur Heart J. 2000;21:1000–8.
   PubMedGoogle Scholar
• Schindhelm RK, van der Zwan LP, Teerlink T, Scheffer PG. Myeloperoxidase: A useful biomarker for cardiovascular disease risk stratification? Clin Chem. 2009;55:1462–70.
   PubMed Web of Science ®Google Scholar
• Frangogiannis NG. The immune system and cardiac repair. Pharmacol Res. 2008;58:88–111.
   PubMed Web of Science ®Google Scholar
• Tse HF, Yiu KH, Lau CP. Bone marrow stem cell therapy for myocardial angiogenesis. Curr Vasc Pharmacol. 2007 5:103–12.
   PubMed Web of Science ®Google Scholar
• Prabhakar U, Eirikis E, Miller BE, Davis HM. Multiplexed cytokine sandwich immunoassays: Clinical applications. Methods Mol Med. 2005;114:223–32.
   Google Scholar
• Elshal MF, McCoy JP. Multiplex bead array assays: Performance evaluation and comparison of sensitivity to ELISA. Methods 2006;38:317–23.
   PubMed Web of Science ®Google Scholar
• Kraaijeveld AO, de Jager SC, van Berkel TJ, Biessen EA, Jukema JW. Chemokines and atherosclerotic plaque progression: Towards therapeutic targeting? Curr Pharm Des. 2007; 13:1039–52.
   Google Scholar
• Kraaijeveld AO, de Jager SC, de Jager WJ, Prakken BJ, McColl SR, Haspels I, . CC chemokine ligand-5 (CCL5/ RANTES) and CC chemokine ligand-18 (CCL18/PARC) are specific markers of refractory unstable angina pectoris and are transiently raised during severe ischemic symptoms. Circulation 2007;116:1931–41.
   PubMed Web of Science ®Google Scholar
• De Jager SC, Kraaijeveld AO, Grauss RW, de Jager W, Liem SS, van der Hoeven BL, . CCL3 (MIP-1 alpha) levels are elevated during acute coronary syndromes and show strong prognostic power for future ischemic events. J Mol Cell Cardiol. 2008;45:446–52.
   PubMed Web of Science ®Google Scholar
• Martins TB, Anderson JL, Muhlestein JB, Horne BD, Carlquist JF, Roberts WL, . Risk factor analysis of plasma cytokines in patients with coronary artery disease by a multiplexed fluorescent immunoassay. Am J Clin Pathol. 2006 125:906–13.
   PubMed Web of Science ®Google Scholar
• Zineh I, Luo X, Welder GJ, Debella AE, Wessel TR, Arant CB, . Modulatory effects of atorvastatin on endothelial cell-derived chemokines, cytokines, and angiogenic factors. Pharmacotherapy 2006;26:333–40.
   Google Scholar
• Inoue T, Komoda H, Nonaka M, Kameda M, Uchida T, Node K. Interleukin-8 as an independent predictor of long-term clinical outcome in patients with coronary artery disease. Int J Cardiol. 2008;124:319–25.
   PubMed Web of Science ®Google Scholar
• Lee BC, Hsu HC, Tseng WY, Su MY, Chen SY, . Effect of cardiac rehabilitation on angiogenic cytokines in postinfarction patients. Heart 2009;95:1012–8.
   Google Scholar
• Schirmer SH, van Nooijen FC, Piek JJ, van Royen N. Stimulation of collateral artery growth: travelling further down the road to clinical application. Heart 2009;95:191–7.
   PubMed Web of Science ®Google Scholar
• Leng SX, McElhaney JE, Walston JD, Xie D, Fedarko NS, Kuchel GA. ELISA and multiplex technologies for cytokine measurement in inflammation and aging research. J Gerontol A Biol Sci Med Sci. 2008 63:879–84.
   PubMed Web of Science ®Google Scholar
• Knight PR, Sreekumar A, Siddiqui J, Laxman B, Copeland S, Chinnaiyan A, Remick DG. Development of a sensitive microarray immunoassay and comparison with standard enzyme-linked immunoassay for cytokine analysis. Shock 2004;21:26–30.
   PubMed Web of Science ®Google Scholar
• Kellar KL, Kalwar RR, Dubois KA, Crouse D, Chafin WD, Kane BE. Multiplexed fluorescent bead-based immunoassays for quantitation of human cytokines in serum and culture supernatants. Cytometry 2001;45:27–36.
   PubMedGoogle Scholar
• Liew M, Groll MC, Thompson JE, Call SL, Moser JE, Hoopes JD, . Validating a custom multiplex ELISA against individual commercial immunoassays using clinical samples. Biotechniques 2007;42:327–33.
   Web of Science ®Google Scholar
• Elshal MF, McCoy JP. Multiplex bead array assays: performance evaluation and comparison of sensitivity to ELISA. Methods 2006;38:317–23.
   PubMed Web of Science ®Google Scholar
• Khan SS, Smith MS, Reda D, Suffredini AF, McCoy JP Jr. Multiplex bead array assays for detection of soluble cytokines: Comparisons of sensitivity and quantitative values among kits from multiple manufacturers. Cytometry B Clin Cytom. 2004;61:35–9.
   PubMed Web of Science ®Google Scholar
• Lash GE, Scaife PJ, Innes BA, Otun HA, Robson SC, Searle RF, . Comparison of three multiplex cytokine analysis systems: Luminex, Searchlight and FAST Quant. J Immunol Methods 2006;309:205–8.
   PubMed Web of Science ®Google Scholar
• Mendoza LG, McQuary P, Mongan A, Gangadharan R, Brignac S, Eggers M. High-throughput microarray-based enzyme-linked immunosorbent assay (ELISA). Biotechniques 1999;27:778–80.
   PubMed Web of Science ®Google Scholar
• Ling MM, Ricks C, Lea P. Multiplexing molecular diagnostics and immunoassays using emerging microarray technologies. Expert Rev Mol Diagn. 2007;7:87–98.
   PubMed Web of Science ®Google Scholar
• Clerico A. Increasing impact of laboratory medicine in clinical cardiology. Clin Chem Lab Med. 2003;41:871–83.
   Google Scholar
• Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease. The present and the future. J Am Coll Cardiol. 2006 48:1–11.
   PubMed Web of Science ®Google Scholar
• Rosalki SB, Roberts R, Katus HA, . Cardiac biomarkers for detection of myocardial infarction: perspectives from past to present. Clin Chem. 2004;50:2205–13.
   PubMed Web of Science ®Google Scholar
• Vasan S. Biomarkers of cardiovascular disease: molecular basis and practical consideration. Circulation 2006 113:2335–62.
   PubMed Web of Science ®Google Scholar
• Estensen ME, Hognestad A, Syversen U, . Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction. Am Heart J. 2006; 927:el–e6.
   Google Scholar
• Lemarié CA, Paradis P, Schiffrin EL. New insights on signaling cascades induced by cross-talk between angiotensin II and aldosterone. J Mol Med. 2008;86:673–8.
   Google Scholar
• de Lemos JA, Lloyd-Jones DM. Multiple biomarker panels for cardiovascular risk assessment. N Engl J Med. 2008 358:2172–4.
   PubMed Web of Science ®Google Scholar
• Reichlin T, Hochholzer W, Bassetti S, . Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med. 2009;361:858–67.
   PubMed Web of Science ®Google Scholar
• Melander O, Newton-Cheh C, Almgren P, . Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 2009;302:49–57.
   PubMed Web of Science ®Google Scholar
• Khot UN, Khot MB, Bajzer CT, . Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003;290:898–904.
   PubMed Web of Science ®Google Scholar
• Zethelius B, Berglund L, Sundström J, . Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008;358:2107–16.
   PubMed Web of Science ®Google Scholar
• Wang TJ, Gona P, Larson MG, . Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355:2631–9.
   PubMed Web of Science ®Google Scholar
• Folsom AR, Chambless LE, Ballantyne CM, . An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: The atherosclerosis risk in communities study. Arch Intern Med. 2006;166:1368–73.
   PubMed Web of Science ®Google Scholar
• Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157–72 [discussion 207–12].
   PubMed Web of Science ®Google Scholar
• Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: The Reynolds risk score. JAMA 2007;297:611–9.
   PubMed Web of Science ®Google Scholar
• Pepe MS. The statistical evaluation of medical tests for classification and prediction. Oxford University Press; 2003.
   Google Scholar